Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback